ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2025
Treatment package time in high-risk oral cavity squamous cell carcinoma: where are we failing and at what cost?
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcriptome-based model for predicting radiotherapy response in HNSCC patients.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The gold-standard of treatment for oral cavity squamous cell carcinoma (OCSCC) is surgery and adjuvant chemoradiotherapy (CRT) in the sub-group of high-risk patients. In this group of patients, treatment time is an important factor in clinical outcomes. We aim to study the influence of the treatment package time (TPT). Materials and methods: We conducted a retrospective study of patients with high-risk OCSCC managed with surgery followed by adjuvant CRT between January 2017 and December 2020. TPT was defined as the time between surgery and the last fraction of radiotherapy. We categorized TPT according to an optimal cut-off point. The Kaplan-Meier methodology was used to calculate 5-year survival. Results: We included 79 patients, median age: 60 years (range: 39-70 years), majority were male (84.8%, n = 67) and smokers (73.4%, n = 58). Extra-nodal extension (ENE) and positive resection/< 1 mm margin were found in 51.9% (n = 41) and 84.8% (n = 67) of cases, respectively. Median radiotherapy dose: 66 Gy. Median cisplatin dose: 300 mg/m Conclusions: Our institution cohort of high risk OCSSC treated with surgery followed by adjuvant CRT had a prolonged TPT (median 109 days). Within our cohort, a TPT > 104 days was found to have a worse OS and DFS, with a nonsignificant impact on locoregional or distant disease-free survival. This highlights the need to optimize the multimodal cancer care pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.